RU2008142359A - Композиция человеческого моноклонального антитела к igf-1r - Google Patents

Композиция человеческого моноклонального антитела к igf-1r Download PDF

Info

Publication number
RU2008142359A
RU2008142359A RU2008142359/15A RU2008142359A RU2008142359A RU 2008142359 A RU2008142359 A RU 2008142359A RU 2008142359/15 A RU2008142359/15 A RU 2008142359/15A RU 2008142359 A RU2008142359 A RU 2008142359A RU 2008142359 A RU2008142359 A RU 2008142359A
Authority
RU
Russia
Prior art keywords
concentration
igf
humat
histidine
polysorbate
Prior art date
Application number
RU2008142359/15A
Other languages
English (en)
Russian (ru)
Inventor
Адельберт ГРОССМАНН (DE)
Адельберт ГРОССМАНН
Ханс-Кристиан МАЛЕР (CH)
Ханс-Кристиан МАЛЕР
Астрид ПАППЕНБЕРГЕР (CH)
Астрид ПАППЕНБЕРГЕР
Оливер Борис ШТАУХ (DE)
Оливер Борис Штаух
Ян Олаф ШТРАКЕ (DE)
Ян Олаф ШТРАКЕ
Original Assignee
Ф.Хоффманн-Ля Рош Аг (Ch)
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг (Ch), Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг (Ch)
Publication of RU2008142359A publication Critical patent/RU2008142359A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2008142359/15A 2006-03-28 2007-03-19 Композиция человеческого моноклонального антитела к igf-1r RU2008142359A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06111848 2006-03-28
EP06111848.5 2006-03-28

Publications (1)

Publication Number Publication Date
RU2008142359A true RU2008142359A (ru) 2010-05-10

Family

ID=37025222

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008142359/15A RU2008142359A (ru) 2006-03-28 2007-03-19 Композиция человеческого моноклонального антитела к igf-1r

Country Status (18)

Country Link
EP (1) EP1998806A1 (zh)
JP (1) JP2009531371A (zh)
KR (1) KR20080104160A (zh)
CN (1) CN101410137A (zh)
AR (1) AR060130A1 (zh)
AU (1) AU2007229554A1 (zh)
BR (1) BRPI0709229A2 (zh)
CA (1) CA2647111A1 (zh)
CL (1) CL2007000797A1 (zh)
CR (1) CR10295A (zh)
EC (1) ECSP088778A (zh)
IL (1) IL193904A0 (zh)
MA (1) MA30345B1 (zh)
MX (1) MX2008012295A (zh)
NO (1) NO20083895L (zh)
RU (1) RU2008142359A (zh)
TW (1) TW200815029A (zh)
WO (1) WO2007110339A1 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110070225A1 (en) * 2006-11-12 2011-03-24 Pierre Goldbach Beta antibody parenteral formulation
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
WO2009007272A1 (en) * 2007-07-10 2009-01-15 F. Hoffmann-La Roche Ag Novel formulation
US20100249384A1 (en) * 2007-11-29 2010-09-30 Stefan Hepbildikler Immunoglobulin aggregates
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
WO2010069858A1 (en) * 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
MX2012013586A (es) * 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
JP6014116B2 (ja) 2011-03-31 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
CN102363040B (zh) * 2011-10-21 2013-05-01 北京锐瑟科技有限公司 用于粘膜组织的抗微生物肽制剂
SG11201508911PA (en) 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
CN103505729B (zh) * 2013-05-24 2015-10-28 华北制药集团新药研究开发有限责任公司 一种稳定的狂犬病毒人源抗体组合制剂
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
MX2016008782A (es) 2014-01-15 2016-09-08 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
CA2950392A1 (en) * 2014-05-28 2015-12-03 Nono Inc. Lyophilized formulation of tat-nr2b9c with acetylation scavenger
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
IL302486A (en) 2015-06-24 2023-06-01 Hoffmann La Roche Antibodies against the transnephrine receptor with adapted affinity
KR20180054791A (ko) * 2015-09-28 2018-05-24 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 안정한 항-pd-1 항체 약학적 제조물 및 의료에서의 그의 적용
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PE20231655A1 (es) 2015-10-02 2023-10-17 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso
CN106199007B (zh) * 2016-08-03 2017-04-05 烟台普罗吉生物科技发展有限公司 蛋白保护剂
KR102369014B1 (ko) 2016-08-16 2022-03-02 리제너론 파아마슈티컬스, 인크. 혼합물로부터 개별 항체들을 정량하는 방법
KR20230119729A (ko) 2016-10-25 2023-08-16 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
TW202005694A (zh) 2018-07-02 2020-02-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
CN114324882B (zh) * 2020-10-12 2022-12-27 广东菲鹏生物有限公司 蛋白稳定剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE230277T1 (de) * 1997-06-13 2003-01-15 Genentech Inc Stabilisierte antikörperformulierung
JP2004531217A (ja) * 2001-01-05 2004-10-14 ファイザー・インク インスリン様成長因子ｉ受容体に対する抗体
JP4317010B2 (ja) * 2001-07-25 2009-08-19 ピーディーエル バイオファーマ，インコーポレイティド ＩｇＧ抗体の安定な凍結乾燥医薬製剤
ATE549359T1 (de) * 2003-04-02 2012-03-15 Hoffmann La Roche Antikörper gegen den insulinähnlichen wachstumsfaktor i-rezeptor und deren verwendungen
ZA200507757B (en) * 2003-04-04 2007-01-31 Genentech Inc High concentration antibody and protein formulations
AR046071A1 (es) * 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
DE602004029581D1 (de) * 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper

Also Published As

Publication number Publication date
BRPI0709229A2 (pt) 2011-06-28
MX2008012295A (es) 2008-10-09
ECSP088778A (es) 2008-10-31
JP2009531371A (ja) 2009-09-03
WO2007110339A1 (en) 2007-10-04
IL193904A0 (en) 2011-08-01
CN101410137A (zh) 2009-04-15
TW200815029A (en) 2008-04-01
AU2007229554A1 (en) 2007-10-04
MA30345B1 (fr) 2009-04-01
NO20083895L (no) 2008-10-24
EP1998806A1 (en) 2008-12-10
CR10295A (es) 2008-10-06
CL2007000797A1 (es) 2008-01-25
KR20080104160A (ko) 2008-12-01
AR060130A1 (es) 2008-05-28
CA2647111A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
RU2008142359A (ru) Композиция человеческого моноклонального антитела к igf-1r
RU2010129481A (ru) Препарат антитела
US8795627B2 (en) Treatment of liver disorders by administration of RAP conjugates
US10093728B2 (en) Pharmaceutical formulations of TNF-alpha antibodies
JP5432183B2 (ja) タンパク質およびペプチドの治療薬の経口投与に関する方法および組成物
US9427480B2 (en) Duocarmycin ADCs for use in treatment of endometrial cancer
KR100942399B1 (ko) Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제
RU2009126420A (ru) Парентеральная лекарственная форма антитела к абета
SG193146A1 (en) Subcutaneous anti-her2 antibody formulation
CA2971414A1 (en) Methods of treating tissue calcification
HRP20230576T1 (hr) Rekombinantna ljudska kisela alfa-glukozidaza
JP2006137678A (ja) インターロイキン−２組成物
US20210379143A1 (en) Drug containing recombinant mistletoe lectins for treating
JP3927954B2 (ja) カンプトテシン誘導体含有水性製剤およびそれを凍結乾燥した医薬組成物
CA2554169A1 (en) Myocardial perfusion imaging using adenosine receptor agonists
US20220339241A1 (en) Stable formulations of recombinant proteins
Albertioni et al. Kinetics and metabolism of 2-chloro-2′-deoxyadenosine and 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine in the isolated perfused rat liver
EP1112066B1 (en) Use of methoxymorpholino doxorubicin for the treatment of a liver tumor
CN103224557B (zh) 一种长效型成纤维细胞生长因子-23拮抗剂的开发
WO2012144579A1 (ja) 溶液状抗体製剤
US20220202914A1 (en) Alkaline phosphate-based oncology treatments
US20210330801A1 (en) Novel protein drug conjugate formulation
WO1991016916A1 (en) Antineoplastic agent
JP2003026605A (ja) 難・低吸収性薬物用吸収促進剤Ｌａｂｒａｓｏｌの改善技術
RU2006127167A (ru) Визуализация перфузии миокарда с использованием агонистов аденозиновых рецепторов

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110725